Integra LifeSciences (NASDAQ:IART – Get Free Report) posted its quarterly earnings data on Monday. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01, Briefing.com reports. Integra LifeSciences had a net margin of 2.63% and a return on equity of 14.27%. The company had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. During the same quarter last year, the firm posted $0.71 earnings per share. The business’s quarterly revenue was up 9.7% on a year-over-year basis.
Integra LifeSciences Stock Performance
Shares of NASDAQ:IART traded down $0.28 during trading on Tuesday, reaching $25.14. 602,631 shares of the company’s stock traded hands, compared to its average volume of 1,119,833. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.68 and a quick ratio of 3.35. The company has a 50 day moving average of $29.72 and a 200-day moving average of $33.65. Integra LifeSciences has a 12 month low of $22.36 and a 12 month high of $46.09. The stock has a market capitalization of $1.98 billion, a P/E ratio of 50.84, a price-to-earnings-growth ratio of 1.14 and a beta of 1.11.
Insider Buying and Selling at Integra LifeSciences
In related news, Chairman Stuart Essig purchased 52,641 shares of the business’s stock in a transaction that occurred on Thursday, May 23rd. The shares were acquired at an average price of $28.49 per share, with a total value of $1,499,742.09. Following the acquisition, the chairman now owns 487,922 shares in the company, valued at approximately $13,900,897.78. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 3.10% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on IART
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
See Also
- Five stocks we like better than Integra LifeSciences
- Investing in Travel Stocks Benefits
- Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
- Stock Dividend Cuts Happen Are You Ready?
- This Semiconductor Stock Is ON Track for a New High
- How to Use Stock Screeners to Find Stocks
- Why SoFi Stock is an Unmissable Growth Opportunity
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.